妊娠16周前或后开始抗血小板治疗预防子痫前期:个体参与者数据Meta分析
本研究利用围产期抗血小板国际研究协作组的个体参与者数据,纳入31项随机试验的32217名女性和32819名婴儿,预设亚组分析比较妊娠16周前与16周及以上开始抗血小板治疗对子痫前期等4项结局的影响。结果显示4项结局的治疗效应在两组间均无显著交互作用,结论认为无论16周前后开始,低剂量阿司匹林等抗血小板药物的效应一致。
要点
- 子痫前期风险RR:<16周组0.90(95%CI 0.79-1.03;17项试验,9241名女性),≥16周组0.90(95%CI 0.83-0.98;22项试验,21429名女性),交互检验P=0.98。
- 婴儿死亡RR:<16周组0.89(95%CI 0.73-1.09;15项试验,8626名女性),≥16周组0.92(95%CI 0.79-1.07;21项试验,22336名女性),交互检验P=0.80。
- 小于胎龄儿RR:<16周组0.76(95%CI 0.61-0.94;13项试验,6393名女性),≥16周组0.95(95%CI 0.84-1.08;18项试验,14996名女性),交互检验P=0.08。
核心结论
- 低剂量阿司匹林及其他抗血小板药物对子痫前期及其并发症的效应一致,无论妊娠16周前还是16周及以上开始治疗。
- 子痫前期风险增高的女性应接受抗血小板治疗,无论首次就诊在妊娠16周前还是16周及以上。
研究设计与样本
- 基于围产期抗血小板国际研究协作组已发表的个体参与者数据Meta分析,共纳入31项随机试验的32217名女性和32819名婴儿。
- 采用预设亚组分析,按随机分组时妊娠<16周与≥16周比较抗血小板药物(低剂量阿司匹林或其他抗血小板药)与安慰剂或无治疗的效应。
- 分析4项预设主要结局:子痫前期、婴儿死亡、34周前早产、小于胎龄儿;使用RevMan软件合并个体参与者数据,采用I²统计量评估异质性,χ²交互检验评估亚组间差异显著性(P<.05)。
主要发现
- 子痫前期:<16周组RR 0.90(95%CI 0.79-1.03;17项试验,9241名女性),≥16周组RR 0.90(95%CI 0.83-0.98;22项试验,21429名女性),交互检验P=0.98。
- 婴儿死亡:<16周组RR 0.89(95%CI 0.73-1.09;15项试验,8626名女性),≥16周组RR 0.92(95%CI 0.79-1.07;21项试验,22336名女性),交互检验P=0.80。
- 34周前早产:<16周组RR 0.90(95%CI 0.77-1.04;19项试验,9155名女性),≥16周组RR 0.91(95%CI 0.82-1.00;25项试验,22117名女性),交互检验P=0.91。
- 小于胎龄儿:<16周组RR 0.76(95%CI 0.61-0.94;13项试验,6393名女性),≥16周组RR 0.95(95%CI 0.84-1.08;18项试验,14996名女性),交互检验P=0.08。
临床怎么用
- 子痫前期风险增高的女性应接受抗血小板治疗,无论首次就诊在妊娠16周前还是16周及以上。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimum time for commencing antiplatelet therapy for the prevention of preeclampsia and its complications is unclear. Aggregate data meta-analyses suggest that aspirin is more effective if given prior to 16 weeks' gestation, but data are limited because of an inability to place women in the correct gestational age subgroup from relevant trials. OBJECTIVE: The objective of the study was to use the large existing individual participant data set from the Perinatal Antiplatelet Review of International Studies Collaboration to assess whether the treatment effects of antiplatelet agents on preeclampsia and its complications vary based on whether treatment is started before or after 16 weeks' gestation. STUDY DESIGN: A meta-analysis of individual participant data including 32,217 women and 32,819 babies recruited to 31 randomized trials comparing low-dose aspirin or other antiplatelet agents with placebo or no treatment for the prevention of preeclampsia has been published previously. Using this existing data set, we performed a prespecified subgroup analysis based on gestation at randomization to antiplatelet agents before 16 weeks, compared with at or after 16 weeks, for 4 of the main outcomes prespecified in the Perinatal Antiplatelet Review of International Studies protocol: preeclampsia, death of baby, preterm birth before 34 weeks, and small-for-gestational-age baby. Individual participant data for the subgroups were combined in a meta-analysis using RevMan software. Heterogeneity was assessed with the I2 statistic. The χ2 test for interaction was used to assess statistically significant (P < .05) differences in treatment effect between subgroups. RESULTS: There was no significant difference in the effects of antiplatelet therapy for women randomized before 16 weeks' gestation compared with those randomized at or after 16 weeks for any of the 4 prespecified outcomes: preeclampsia, relative risk, 0.90, (95% confidence interval, 0.79-1.03; 17 trials, 9241 women) for <16 weeks and relative risk, 0.90 (95% confidence interval, 0.83-0.98; 22 trials, 21,429 women) for ≥16 weeks (interaction test, P = .98); death of baby, relative risk, 0.89 (95% confidence interval, 0.73-1.09; 15 trials, 8626 women) for <16 weeks and relative risk, 0.92 (95% confidence interval, 0.79-1.07; 21 trials, 22,336 women) for ≥16 weeks (interaction test, P = .80); preterm birth prior to 34 weeks, relative risk, 0.90 (95% confidence interval, 0.77-1.04; 19 trials, 9155 women) for <16 weeks and relative risk, 0.91 (95% confidence interval, 0.82-1.00; 25 trials, 22,117 women) for ≥16 weeks (interaction test, P = .91); and small-for-gestational-age baby, relative risk, 0.76 (95% confidence interval, 0.61-0.94; 13 trials, 6393 women) for <16 weeks and relative risk, 0.95 (95% confidence interval, 0.84-1.08; 18 trials, 14,996 women) for ≥16 weeks (interaction test, P = .08). CONCLUSION: The effect of low-dose aspirin and other antiplatelet agents on preeclampsia and its complications is consistent, regardless of whether treatment is started before or after 16 weeks' gestation. Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation.
引用
- Meher S, Duley L, Hunter K, et al. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2016. PMID: 27810551. doi:10.1016/j.ajog.2016.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。